Dyne Therapeutics is a biotechnology company dedicated to improving the lives of individuals affected by genetically driven neuromuscular diseases. The company focuses on developing innovative therapeutics that target muscle and the central nervous system to address the underlying causes of conditions such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also advancing preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. With a mission to deliver functional improvements for patients and their communities, Dyne Therapeutics is committed to advancing clinical and regulatory programs that enhance the quality of life for those impacted by these challenging diseases.